TG Therapeutics Provides Business Update and Reports Second Quarter 2019 Financial Results
Last tg therapeutics, inc earnings: 11/12 07:34 am
Check Earnings Report
US:NASDAQ Investor Relations: ir.tgtherapeutics.com
NEW YORK, Aug. 09, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2019 and recent company developments. Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, stated, "As we enter into the second half of the year, we are pleased with the progress made thus far and excited for the upcoming milestones. With a well-defined path to a regulatory submission for umbralisib in marginal zone lymphoma, we feel confident that we are at a pivotal point in our Company’s lifecycle.” Mr. Weiss continued, “As we prepare for our first filing in MZL, we are also building a top-notch commercial organization which will fuel the long-term success of TG. And with pivotal data readouts also expected in CLL and MS over the next 6-12 months, we believe we are at the beginning of an extremely exciting transformational period for our Company.” Recent Developments and Highlights Marginal Zone
[Read more]
| Impact snapshot | Event time: | TGTX | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
TGTX alerts
TGTX alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TGTX alerts
High impacting TG Therapeutics, Inc news events
Weekly update
A roundup of the hottest topics
TGTX
News
- TG Therapeutics to Present Results from the ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab in Multiple Sclerosis at the Upcoming American Academy of Neurology 73rd Annual MeetingGlobeNewswire
- TG Therapeutics to Present at the H.C. Wainwright Global Life Sciences ConferenceGlobeNewswire
- TG Therapeutics Inc (TGTX) Q4 2020 Earnings Call Transcript [The Motley Fool]The Motley Fool
- TG Therapeutics' (TGTX) CEO Michael Weiss on Q4 2020 Results - Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2020 Financial ResultsGlobeNewswire
- More
TGTX
SEC Filings
- 3/2/21 - Form 8-K
- 3/1/21 - Form 10-K
- 2/16/21 - Form SC
- TGTX's page on the SEC website
- More